Inicio・Lista de Acciones・Compugen Ltd

Compugen Ltd

Cerrado

2.48 1.22

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2.46

Máximo

2.48

Métricas clave
By Trading Economics
Ingresos	663K -7M
Ventas	426K 2.6M
P/B Media del Sector	6.526 56.432
BPA	-0.07
Margen de beneficios	-269.254
Empleados	75
EBITDA	665K -7M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+100.8% upside

Dividendos
By Acuity
Próximas Ganancias	9 nov 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	9.8M 235M
Apertura anterior	1.26
Cierre anterior	2.48

Compugen Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

19 sept 2026, 23:31 UTC

China's Loan Prime Rate announcement on September 21, 2026, is anticipated at 0.03%, amid global tightening trends influenced by rising inflation and Japan's recent rate hike to 1.25%.

19 sept 2026, 23:31 UTC

China's Loan Prime Rate expected to hold at 3.50% on September 21, amid stable market sentiment and focus on international cooperation.

19 sept 2026, 23:11 UTC

U.S. Mortgage Rates Hit 6.97% Amid Fed Rate Hike and Inflation Concerns, Signaling Potential Further Increases Ahead

19 sept 2026, 23:11 UTC

Cautious Market Sentiment Ahead of Chicago Fed National Activity Index Release Amid Disappointing Economic Indicators

19 sept 2026, 23:01 UTC

Avalanche is advancing sharply, continuing its strong upward trend, despite earlier pulling back from a session high, and trading well above its 20-day moving average.

19 sept 2026, 23:01 UTC

Correlated Moves

XRP is advancing, continuing its upward trend since Friday's close, influenced by ongoing geopolitical tensions and recent interest rate hikes by major central banks.

19 sept 2026, 22:51 UTC

Correlated Moves

The Russell 2000 Index is little changed in after-market hours, remaining near the lower end of its one-month range amid ongoing geopolitical tensions.

19 sept 2026, 22:51 UTC

Correlated Moves

Macro News

The Dow Jones Index (US) is trading lower in after-market hours, reflecting minimal movement since Friday's close amid ongoing geopolitical tensions and a new Lockheed Martin contract.

19 sept 2026, 22:51 UTC

The FTSE 100 Index is trading lower in after-market hours, positioned below its 20-day moving average amid ongoing geopolitical tensions affecting energy prices.

19 sept 2026, 22:31 UTC

UK Consumer Confidence Index Forecasted at -16.0 Amid Cautious Market Sentiment and Rising Cost-of-Living Concerns

19 sept 2026, 21:41 UTC

Australia's S&P Global Manufacturing PMI Flash set for September 22, with market expectations at neutral 50 amid cautious optimism and inflation concerns.

19 sept 2026, 21:41 UTC

Australia's S&P Global Services PMI Flash release on September 22 faces cautious optimism amid mixed economic signals and global inflation concerns.

19 sept 2026, 21:21 UTC

Brazil's Central Bank to Release COPOM Meeting Minutes Amid Global Interest Rate Shifts, Influencing Market Sentiment on SELIC Decisions

19 sept 2026, 21:11 UTC

UK CBI Distributive Trades Forecasts -50.0 Amidst Recent Retail Sales Rebound, Indicating Mixed Consumer Sentiment Ahead of Q4

19 sept 2026, 20:41 UTC

UK Manufacturing Sector Faces Caution Ahead of September 2026 CBI Industrial Trends Orders Forecasted at -35.0 Amid Mixed Economic Signals and Rising Cost Pressures.

19 sept 2026, 20:41 UTC

API Crude Oil Stock Change Data Release on September 22, 2026, Amidst Volatile Market Influenced by Geopolitical Tensions and Mixed Investor Sentiment.

19 sept 2026, 19:41 UTC

South Korea's Consumer Confidence Index set for release amid bearish market sentiment and rising interest rates, signaling potential consumer caution.

19 sept 2026, 19:41 UTC

Correlated Moves

EUR/NZD is roughly flat since Friday's close, maintaining stability while the market is closed for the weekend and reflecting its position near the upper end of its one-month range.

19 sept 2026, 19:41 UTC

Macro News

Volkswagen's fiscal outlook revision due to Porsche AG goodwill impairment is contributing to a decline in the IBEX 35 Index amid rising geopolitical tensions.

19 sept 2026, 19:41 UTC

Macro News

The A50 Index (China) is modestly higher in after-market trading, amid rising geopolitical tensions and central bank interest rate hikes affecting risk assets.

19 sept 2026, 19:11 UTC

Germany's Ifo Business Climate Index set for September 24 release amid cautious market sentiment and rising inflation expectations.

19 sept 2026, 18:51 UTC

Investors Brace for Cautious S&P Global Composite PMI Flash Release Amid Rising Inflation Concerns in Euro Area

19 sept 2026, 18:51 UTC

South Africa's Inflation Rate Set for Release Amid Cautious Market Sentiment Following July Decline to 4.3%.

19 sept 2026, 18:51 UTC

Investors Brace for S&P Global Services PMI Flash Release Amid Rising Inflation Concerns and Mixed Economic Signals in Euro Area

19 sept 2026, 18:51 UTC

Euro Area's S&P Global Manufacturing PMI Flash set for September 23, with forecasted growth amid rising inflation concerns and cautious investor sentiment.

19 sept 2026, 18:51 UTC

South Africa's Inflation Rate Release on September 23, 2026 Sparks Caution Among Investors Amid Global Economic Pressures.

19 sept 2026, 18:41 UTC

SNB Expected to Maintain 0% Interest Rate Amid Low Inflation and Strong Franc Ahead of September Decision

19 sept 2026, 18:31 UTC

Spain's Balance of Trade report on September 22, 2026, raises concerns over systemic trade deficits amid rising inflation and cautious market sentiment.

19 sept 2026, 18:21 UTC

Germany's S&P Global Services PMI Flash set for September 23, with cautious market sentiment amid rising inflation expectations and mixed economic indicators.

19 sept 2026, 18:21 UTC

Germany's S&P Global Composite PMI Flash Release on September 23 Expected to Reflect Economic Challenges Amid Inflation and Geopolitical Uncertainty.

Comparación entre iguales

Cambio de precio

Compugen Ltd previsión

Precio Objetivo

By TipRanks

100.8% repunte

Estimación a 12 Meses

Media 5 USD 100.8%

Máximo 6 USD

Mínimo 4 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Compugen Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Compugen Ltd Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.